[Oncofertility and breast cancer].
Oncofertilité et cancer du sein.
Adult
Antineoplastic Agents
/ adverse effects
Breast Neoplasms
/ drug therapy
Cryopreservation
/ methods
Embryo, Mammalian
Female
Fertility Preservation
/ methods
Genes, BRCA1
Genes, BRCA2
Humans
Male
Oocytes
Ovary
/ drug effects
Ovulation Induction
/ methods
Pregnancy
Quality of Life
Testis
/ drug effects
Young Adult
Congélation
Controlled ovarian
Cryoconservation
Fertility preservation
In vitro maturation
Maturation in vitro
Oocyte freezing
Ovarian tissue
Préservation
cryopreservation
de cortex ovarien
de la fertilité
ovocytaire Stimulation ovarienne
stimulation
Journal
Bulletin du cancer
ISSN: 1769-6917
Titre abrégé: Bull Cancer
Pays: France
ID NLM: 0072416
Informations de publication
Date de publication:
Dec 2019
Dec 2019
Historique:
entrez:
4
2
2020
pubmed:
6
2
2020
medline:
13
2
2020
Statut:
ppublish
Résumé
Over the past decades, progresses in oncology have improved the recovery rates after numerous malignant diseases, including breast cancer, that strike young adults in childbearing age. Quality of life of young cancer survivors has become a major issue. However, anticancer therapies can have a detrimental impact on fertility. It is now well-established that all patients should receive information about the fertility risks associated with their cancer treatment and the fertility preservation options available. These techniques aim to limit the negative impact of chemotherapy on the ovaries or to preserve gametes before treatment. Currently, oocyte or embryo freezing after controlled ovarian hyperstimulation represents the most effective method for preserving female fertility. Over the past years innovative protocols of ovarian stimulation have been developed to enable breast cancer patients to undergo oocyte or embryo cryopreservation irrespective of the phase of the cycle or without exogenous follicle-stimulating hormone related increase in serum estradiol levels. When controlled ovarian hyperstimualtion cannot be implemented, other techniques such as cryopreservation of ovarian cortex, in vitro maturation or the use of GnRH agonists may be proposed. However, it is important to inform patients that all these fertility preservation techniques do not represent a guarantee of pregnancy.
Identifiants
pubmed: 32008738
pii: S0007-4551(20)30047-3
doi: 10.1016/S0007-4551(20)30047-3
pii:
doi:
Substances chimiques
Antineoplastic Agents
0
Types de publication
Journal Article
Review
Langues
fre
Sous-ensembles de citation
IM
Pagination
S43-S52Informations de copyright
Copyright © 2019 Société Française du Cancer. Publié par Elsevier Masson SAS. Tous droits réservés.